These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1353706

  • 1. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
    Speicher LA, Barone L, Tew KD.
    Cancer Res; 1992 Aug 15; 52(16):4433-40. PubMed ID: 1353706
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of taxol on two human cancer cell lines.
    Banerjee S, Fallis AG, Brown DL.
    Oncol Res; 1997 Oct 15; 9(5):237-48. PubMed ID: 9306431
    [Abstract] [Full Text] [Related]

  • 4. Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
    Aoyama M, MacIsaac D, Bukowski RM, Ganapathi MK.
    Clin Cancer Res; 1998 Apr 15; 4(4):1039-45. PubMed ID: 9563900
    [Abstract] [Full Text] [Related]

  • 5. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
    Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR.
    Cancer Res; 1996 Jun 01; 56(11):2584-9. PubMed ID: 8653701
    [Abstract] [Full Text] [Related]

  • 6. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S, McCauley RA, Dexter DW, Hudes GR.
    Br J Cancer; 2001 Sep 01; 85(5):735-40. PubMed ID: 11531260
    [Abstract] [Full Text] [Related]

  • 7. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 01; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 8. Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells.
    Darby E, An S, Ng C, Hsieh TC, Mallouh C, Wu JM.
    Anticancer Res; 1996 Apr 01; 16(6B):3647-52. PubMed ID: 9042236
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy.
    Lokeshwar BL, Ferrell SM, Block NL.
    Anticancer Res; 1995 Apr 01; 15(1):93-8. PubMed ID: 7733649
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R.
    Semin Oncol; 1995 Jun 01; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [Abstract] [Full Text] [Related]

  • 11. Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
    Eklöv S, Mahdy E, Wester K, Björk P, Malmström PU, Busch C, Nilsson S.
    Anticancer Res; 1996 Jun 01; 16(4A):1819-22. PubMed ID: 8712706
    [Abstract] [Full Text] [Related]

  • 12. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
    Rowinsky EK, Donehower RC, Jones RJ, Tucker RW.
    Cancer Res; 1988 Jul 15; 48(14):4093-100. PubMed ID: 2898289
    [Abstract] [Full Text] [Related]

  • 13. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
    Speicher LA, Sheridan VR, Godwin AK, Tew KD.
    Br J Cancer; 1991 Aug 15; 64(2):267-73. PubMed ID: 1892755
    [Abstract] [Full Text] [Related]

  • 14. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells.
    Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):615-22. PubMed ID: 16025289
    [Abstract] [Full Text] [Related]

  • 15. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.
    Wang M, Tew KD, Stearns ME.
    Anticancer Res; 1987 Dec 15; 7(6):1165-71. PubMed ID: 3327449
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T.
    Cancer Chemother Pharmacol; 2003 Jun 15; 51(6):505-11. PubMed ID: 12709826
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 18. Estramustine-based chemotherapy.
    Hudes G.
    Semin Urol Oncol; 1997 Feb 15; 15(1):13-9. PubMed ID: 9050135
    [Abstract] [Full Text] [Related]

  • 19. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.
    Sheridan VR, Speicher LA, Tew KD.
    Eur J Cell Biol; 1991 Apr 15; 54(2):268-76. PubMed ID: 1879438
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of Taxol-induced cell death are concentration dependent.
    Torres K, Horwitz SB.
    Cancer Res; 1998 Aug 15; 58(16):3620-6. PubMed ID: 9721870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.